Pulse Biosciences (PLSE) Cost of Revenue (2021 - 2025)

Pulse Biosciences' Cost of Revenue history runs 3 years deep, the most recent figure standing at $279000.0 for Q3 2025.

• On a quarterly basis, Cost of Revenue changed N/A year-over-year to $279000.0 in Q3 2025; TTM through Sep 2025 was $279000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $11.9 million, up 506.91% from the prior year.
• Cost of Revenue slipped to $279000.0 in Q3 2025 per PLSE's latest filing, from $1.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $8.4 million in Q3 2022 and bottomed at $279000.0 in Q3 2025.
• The 3-year median for Cost of Revenue is $1.2 million (2021), against an average of $2.0 million.
• Biggest YoY gain for Cost of Revenue was 1055.43% in 2022; the steepest drop was 4.03% in 2022.
• Year by year, Cost of Revenue stood at $1.2 million in 2021, then advanced by 4.03% to $1.3 million in 2022, then plunged by 78.39% to $279000.0 in 2025.
• Per Business Quant, the three latest PLSE Cost of Revenue figures stand at $279000.0 (Q3 2025), $1.3 million (Q4 2022), and $8.4 million (Q3 2022).